JWH-133
Identifiers | |
---|---|
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
JWH-133 (Dimethylbutyl-deoxy-Delta-8-THC) is a potent selective
JWH-133 has been confused with other analogs of
The 3-(1',1'-Dimethylbutyl)-1-deoxy-delta-8-THC is a selective
JWH-133, alongside WIN 55,212-2 and HU-210, is responsible for preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's disease, in addition to preventing cognitive impairment and loss of neuronal markers.[citation needed] This anti-inflammatory action is induced through agonist action at the CB2 receptor, which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids at this receptor completely abolish neurotoxicity related to microglia activation in rat models.[citation needed]
It may be linked with anti-cancer properties, according to pre-trial data from a 2010 study in Madrid.[5]
Legal Status
JWH-133 is not specifically listed in the United States controlled substance act but may be considered an analog of THC (under the Federal Analogue Act) if sold for human consumption.[6]
References
- PMID 27398024.
- ^ "(6AR,10AR)-3-(1,1-Dimethylbutyl)-6A,7,10,10A-tetrahydro-6,6,9-trimethyl-6H-dibenzo[B,D]pyran".
- ^ PMID 10658595.
- ^ PMID 12628666.
- PMID 20649976.
- "Marijuana Compound Halts Breast Cancer Tumor Growth". NORML. August 5, 2010.
- ^ "Federal Register :: Request Access".
Further reading
- Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML (February 2005). "Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation". The Journal of Neuroscience. 25 (8): 1904–1913. PMID 15728830.